The European adult incontinence market is dominated by household names like TENA (Essity) and Hartmann, brands with decades of consumer recognition and billion-euro marketing budgets. Yet for wholesale distributors, pharmacies, and healthcare institutions, brand recognition is only one factor in a complex purchasing decision. Performance metrics, commercial terms, logistics flexibility, and margin potential matter just as much—often more.
This article provides an objective comparison between KERA incontinence products and established market leaders, based on technical specifications, distributor feedback, and real-world wholesale dynamics. Whether you're evaluating a new supplier or diversifying your product range, understanding how KERA stacks up against premium brands can inform smarter procurement decisions.
Market Context: The Economics of Private Label vs. Branded
The global adult incontinence market reached €12.8 billion in 2025, with Europe accounting for approximately €3.2 billion. TENA holds roughly 28% market share across Europe, followed by Hartmann at 14% and a fragmented field of regional and private-label brands comprising the remainder. What's less discussed is that private-label and mid-tier brands collectively represent over 40% of unit volume in pharmacies and care institutions—a testament to their clinical performance and cost-effectiveness.
KERA occupies a deliberate position in this landscape: CE-certified products manufactured to European standards in Belgium, France, and Greece, with absorption performance comparable to premium brands but positioned for distributors seeking better margins without compromising quality. The brand is directly owned by Emmanuil Kokolantonakis and distributed via EASYCARE IKE from Athens, eliminating corporate middlemen and enabling more flexible commercial relationships.
Performance Comparison: Absorption, Fit, and Material Quality
Absorption Capacity
One of the most objective metrics in incontinence product evaluation is absorption capacity, measured in milliliters. Here's how KERA's core products compare to market leaders:
- Day Use (Light-Moderate Incontinence): TENA Pants Plus: 2,500ml | Hartmann MoliCare Premium: 2,600ml | KERA Pants Day: 2,500-2,800ml
- Standard Protection: TENA Pants Super: 3,000ml | Hartmann MoliCare Mobile: 2,900ml | KERA Pants Plus: 2,800-3,200ml
- Night/Heavy Incontinence: TENA Pants Night: 3,400ml | Hartmann MoliCare Premium Maxi: 3,600ml | KERA Pants Super Night: 3,400-3,700ml
- Tape Diapers (Slip-Style): TENA Slip Maxi: 3,800ml | Hartmann MoliCare Slip Super: 4,000ml | KERA Slip Night: 3,500-4,300ml
The data shows KERA products consistently match or exceed premium brand absorption across categories. In independent distributor testing, KERA Pants Super Night demonstrated 97% retention after 8 hours of simulated overnight use, comparable to TENA's flagship night product. The key difference isn't performance—it's brand premium pricing.
Material Quality and Skin Tolerance
TENA and Hartmann invest heavily in dermatologically-tested materials, odor control, and breathable outer layers. KERA products manufactured in Belgium and France utilize similar supplier networks for superabsorbent polymers (SAP) and non-woven fabrics, sourced from European manufacturers including technical-grade SAP from BASF and Evonik. All KERA products are CE-certified and comply with EN ISO 15621 standards for absorbent incontinence aids.
Dermatological tolerance is comparable: TENA uses pH-balanced materials and aloe vera treatments; Hartmann emphasizes curly fiber technology for rapid absorption; KERA products feature soft polypropylene backsheets and elastic waistbands designed for extended wear. In practice, skin compatibility comes down to individual user tolerance rather than categorical brand differences.
The Underpad Advantage: KERA's Unique 75x90cm Dimension
One area where KERA offers a genuine market advantage is in underpads (bed protectors). While TENA and Hartmann produce standard 60x90cm and 60x60cm underpads, KERA manufactures a 75x90cm underpad—a dimension specifically designed for European hospital beds (standard width 70-80cm) that provides better lateral coverage without excess material waste.
This seemingly minor specification addresses a real clinical need: standard 60cm-wide pads often leave gaps on wider hospital beds, while 80x180cm pads are oversized and wasteful for single-patient use. The 75x90cm format has gained traction among care institutions in France and Belgium, where KERA Bed Super is manufactured. For distributors targeting healthcare facilities, this product fills a niche that market leaders have largely overlooked. You can explore the full range of KERA underpads and other products on our products page.
Commercial Terms: Where KERA Differentiates
Beyond product specifications, wholesale procurement decisions hinge on commercial flexibility, logistics, and margin structures. This is where KERA's direct-ownership model creates tangible advantages.
Pricing and Margins
TENA and Hartmann typically operate through tiered distributor networks with non-negotiable pricing structures enforced by corporate procurement teams. Wholesale prices for TENA Pants Super range from €0.75-€0.95 per unit depending on volume, with distributor margins around 18-22%. Hartmann's pricing is similar, with slightly better margins (22-25%) for exclusive partnerships.
KERA's wholesale pricing for comparable products ranges from €0.52-€0.68 per unit, enabling distributor margins of 30-38% while remaining price-competitive at retail. This isn't a quality trade-off—it's a structural advantage from eliminating corporate overhead and working directly with manufacturing partners. For new distributors, KERA offers an additional 5% free goods bonus during the first six months, effectively increasing initial margins to 35-43%.
Minimum Order Quantities and Payment Terms
TENA and Hartmann require minimum order volumes of 2-3 full containers (40-50 pallets) for ex-works pricing, with 60-day payment terms standard for established accounts. Smaller orders go through secondary distributors at higher unit costs.
KERA's MOQ is 1x 40ft HC container per quarter—equivalent to roughly 18-22 pallets depending on product mix—with flexible payment terms: 30% deposit and 70% before loading. This lower entry barrier makes KERA accessible to regional distributors and pharmacy groups who can't justify multi-container orders. Exclusive territory agreements are available on a 12-month renewable basis, far shorter than the typical 3-5 year commitments required by major brands.
Logistics and Multi-Warehouse Flexibility
TENA ships primarily from central European warehouses in Germany and Sweden, with 10-14 day lead times for most EU destinations. Hartmann operates similarly from German facilities. KERA maintains stock across three EU locations—Belgium (Buggenhout), France (Hénin-Beaumont), and Greece (Oinofyta)—enabling faster regional fulfillment. A French distributor can receive KERA Lady pads in 5-7 days from Hénin-Beaumont, while a Southern European buyer benefits from competitive freight costs ex-Greece.
This multi-warehouse model also facilitates mixed-product orders: a distributor can combine Belgian-manufactured KERA Pants with French-made underpads in a single container, optimizing SKU diversity without sacrificing logistics efficiency. Learn more about how our distributor program supports flexible ordering on our distributor partnerships page.
Brand Equity vs. Private Label Strategy
The most significant difference between KERA and market leaders isn't product quality or commercial terms—it's brand investment. TENA spends an estimated €150-200 million annually on consumer advertising, sponsorships, and digital marketing across Europe. Hartmann invests similarly in healthcare professional education and clinical partnerships. This brand equity translates to consumer pull-through in pharmacies and care institutions, where patients or families may specifically request "TENA" rather than a generic product.
KERA doesn't compete on consumer brand recognition. Instead, it appeals to distributors who control placement and can educate end-users on product performance. In institutional settings—nursing homes, hospitals, home care agencies—purchasing decisions are made by procurement teams focused on cost-per-patient-day and clinical outcomes, not brand logos. In these channels, KERA's performance-to-price ratio is a competitive strength.
For pharmacies and retail distributors, KERA can function as a second-tier branded option: a quality alternative positioned 15-25% below premium brands, capturing price-sensitive consumers without resorting to generic private label. In markets like Spain and Portugal, where disposable incomes are lower and price sensitivity is high, this positioning has proven effective.
Regulatory and Quality Certifications
Both TENA and Hartmann hold ISO 13485 (medical device quality management) and ISO 9001 certifications, along with CE marking for all incontinence products. KERA products manufactured in Belgium, France, and Greece are similarly CE-certified and comply with EN ISO 15621 standards. Manufacturing partners undergo regular third-party audits to maintain certification.
For distributors serving healthcare institutions, these certifications are table stakes. KERA meets the same regulatory requirements as market leaders, and products are manufactured in the same facilities that produce private-label lines for European pharmacy chains. In fact, some KERA products share production lines with store brands sold by major French and Belgian pharmacy groups—the difference is branding and commercial terms, not the manufacturing process.
Sustainability and Environmental Considerations
TENA has invested heavily in sustainability initiatives, including plant-based SAP materials, carbon-neutral production targets, and recycling programs. Hartmann similarly promotes eco-friendly materials and sustainable forestry certifications. These initiatives resonate with environmentally-conscious consumers and institutions with green procurement mandates.
KERA's sustainability profile is aligned with European manufacturing standards: products manufactured in Belgium and France comply with EU chemical regulations (REACH), use chlorine-free pulp, and minimize plastic packaging. However, KERA doesn't market sustainability as a primary differentiator—the focus remains on clinical performance and commercial value. For distributors where sustainability is a procurement criterion, KERA meets baseline expectations without premium eco-branding.
Who Should Consider KERA vs. Market Leaders?
The choice between KERA and premium brands depends on your distribution strategy, target market, and margin objectives:
- Choose TENA/Hartmann if: You operate in high-income markets where brand recognition drives sales; your retail customers demand premium brands; you can afford low margins in exchange for high turnover; you have capital for multi-container orders and 3-5 year exclusive agreements.
- Choose KERA if: You serve price-sensitive markets (Spain, Portugal, Eastern Europe); you control placement in pharmacies or institutions and can educate buyers on performance; you need higher margins (30-40%) to support your sales infrastructure; you prefer shorter-term commitments (12-month exclusive agreements); you want logistics flexibility with multi-warehouse EU shipping.
Many distributors adopt a dual strategy: stock TENA or Hartmann as the premium option for brand-conscious consumers, and position KERA as the high-value alternative for cost-conscious buyers. This captures both market segments without cannibalizing sales.
Direct Partnership and Decision-Making Speed
One overlooked advantage of working with KERA is access to the brand owner. Unlike TENA (part of Essity, a €12 billion public company) or Hartmann (a €2 billion corporate group), KERA is directly owned and managed by Emmanuil Kokolantonakis. Commercial negotiations, product customization requests, and exclusive territory discussions happen directly with decision-makers, not through regional sales managers operating within rigid corporate policies.
For distributors seeking bespoke solutions—custom product bundles, co-branded packaging, or territory-specific pricing—this direct relationship enables faster decisions and more creative partnerships. If you're interested in exploring a tailored partnership, you can reach out directly via our contact page.
Conclusion: Performance Parity, Commercial Differentiation
The adult incontinence market is mature and competitive, with product performance increasingly standardized across brands. KERA incontinence products—manufactured in Belgium, France, and Greece to the same European standards as market leaders—deliver comparable absorption, skin tolerance, and fit. The differences lie in brand premium, commercial terms, and go-to-market strategy.
For distributors who value margin flexibility, lower MOQs, and direct partnerships over consumer brand equity, KERA represents a strategic alternative to TENA and Hartmann. The products perform; the certifications are equivalent; the logistics are competitive. What changes is the commercial equation: better margins, shorter commitments, and a partner model that prioritizes distributor success.
In a market where premium brands command shelf space but squeeze margins, KERA offers a path to profitability without compromising clinical quality. For the right distribution strategy, that's a compelling value proposition.